pharma · Atopic Dermatitis · Seborrheic Keratosis · ACRS
Aclaris Therapeutics drug portfolio — 12 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 12 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Aclaris Therapeutics drug portfolio — 12 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
US regulatory status: approved. Molecular target: Parathyroid hormone/parathyroid hormone-related peptide receptor.
Development asset linked to Aclaris Therapeutics in public FDA and regional records.
Development asset linked to Aclaris Therapeutics in public FDA and regional records.
US regulatory status: approved. Molecular target: Estrogen receptor.
US regulatory status: approved. Molecular target: Estrogen receptor.
Development asset linked to Aclaris Therapeutics in public FDA and regional records.
US regulatory status: approved. Mechanism: Unknown.
Development asset linked to Aclaris Therapeutics in public FDA and regional records.
US regulatory status: approved. Mechanism: Adrenergic receptor alpha agonist.
Development asset linked to Aclaris Therapeutics in public FDA and regional records.
Development asset linked to Aclaris Therapeutics in public FDA and regional records.
Development asset linked to Aclaris Therapeutics in public FDA and regional records.